Skip to main content

Table 2 Characteristics of patients who developed active tuberculosis during anti-TNF therapy

From: Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

No

IBD

Sex

Age of anti-TNF (years)

Age of TB (years)

Interval to TB diagnosis (months)

Anti-TNF agents

TST

IGRA

Previous TB treatment

LTBI

TB prophylaxis

Smoking

TB site

1

UC

M

67

68

2

IFX

ND

(−)

No

(−)

ND

Ex

Lung

2

UC

M

66

67

10

IFX

(−)

(−)

No

(−)

ND

Ex

Lung + peritoneum

3

UC

F

42

47

55

IFX

(−)

(−)

No

(−)

ND

(−)

Lung

4

UC

M

53

53

2

IFX

ND

(−)

No

(−)

ND

Ex

Lung

5

UC

M

46

47

14

IFX > ADA

ND

(+)

No

(+)

INH + RFP

Ex

Lung + pleura

6

UC

M

60

60

4

IFX

(−)

(−)

No

(−)

ND

(+)

pleura + pericardium

7

CD

F

33

33

3

IFX

(−)

(−)

No

(−)

ND

Ex

Lung

8

CD

M

59

59

3

IFX

(−)

(−)

No

(−)

ND

Ex

Lung

9

CD

M

26

29

34

ADA

(−)

(+)

No

(+)

INH + RFP

(−)

Lung

10

CD

F

26

30

50

IFX > ADA

(−)

(−)

No

(−)

ND

(−)

Lung

11

CD

M

23

25

27

IFX

ND

(−)

No

(−)

ND

(−)

Lung + LN

12

CD

F

32

32

4

IFX

ND

ND

No

Unknown

ND

(−)

Spleen + LN

13

CD

F

22

25

42

IFX

(−)

(+)

No

(+)

RFP

(−)

Lung

14a

CD

F

37

42

67

IFX

(−)

(−)

No

(−)

ND

(+)

Lung + pleura

15

CD

M

24

32

95

IFX

(−)

(−)

ITBb

(−)

ND

(+)

Lung + pleura

16

CD

M

29

30

5

IFX

(−)

Indeterminate

No

(−)

ND

(−)

Lung

17

CD

F

44

45

14

IFX

(−)

(−)

No

(−)

ND

(−)

Lung

18

CD

M

41

43

17

IFX

(−)

(−)

Lung

(−)

ND

(−)

Lung

19

CD

F

41

43

24

IFX > ADA

(−)

(−)

ITBb

(−)

ND

(−)

pleura

20

CD

F

35

36

11

IFX

(−)

(−)

ITBb

(−)

ND

(−)

Lung + endobronchus

21

CD

M

25

26

1

IFX

ND

(−)

No

(−)

ND

(+)

Lung

  1. TNF, tumor necrosis factor; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; LTBI, latent tuberculosis infection; TB, tuberculosis; TST, tuberculin skin test; IGRA, interferon gamma release assay; IFX, infliximab; ADA, adalimumab; ND, not done; ITB, intestinal tuberculosis; INH, isoniazid; RFP, rifampin; Ex, ex-smoker; LN, lymph node
  2. aThis patent was undergoing treatment for tuberculosis at the end of the study. All other patients were completely cured after tuberculosis treatment
  3. bThese patients with Crohn's disease had a history of medication for tuberculosis to identify intestinal tuberculosis